Oral semaglutide: what the evidence says about the UK's first weight-loss tablet

What the OASIS 4 trial actually found

The MHRA's approval of the Wegovy tablet rested primarily on the OASIS 4 phase 3 trial: 307 adults with obesity or overweight and at least one weight-related condition, none with type 2 diabetes, followed for 64 weeks alongside lifestyle support. The headline result was an average body-weight reduction of roughly 13.6% with oral semaglutide against around 2.4% with placebo. Among participants who stayed fully adherent to treatment throughout the trial, the figure climbed to approximately 16.6%. That distinction matters: the ~17% figure you may see quoted is a per-protocol result, not the average for everyone who started. Both are legitimate; quoting one without the other gives an incomplete picture.

Gastrointestinal side effects were common (reported by around 74% of those on oral semaglutide versus 42% on placebo) though most were mild to moderate and eased as the dose settled. Nausea, indigestion and loose stools were the most frequently cited. More on the Wegovy tablet's full evidence profile is covered separately, including how these figures compare with the injectable form.

For context, the MHRA announcement on 11 June 2026 described this as a significant milestone: the UK becoming the first in Europe to licence an oral GLP-1 for weight management. That regulatory backing, from a Tier-1 UK source, carries weight that forum posts and press speculation do not.

How oral semaglutide reaches the bloodstream

GLP-1 medicines have historically been given by injection because semaglutide (a peptide) is broken down in the stomach before it can be absorbed in useful quantities. The oral version gets around this with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that temporarily raises the local pH around the tablet and allows semaglutide to cross the stomach lining directly into the bloodstream.

The practical consequence of that mechanism is the morning ritual it demands. The tablet needs to be taken first thing, on an empty stomach, with no more than a small sip of plain water, roughly 120 ml. You then wait at least 30 minutes before eating, drinking anything else (including coffee), or taking other oral medicines. If you put the kettle on before you take the tablet, the window is already closing. It is a genuine routine constraint, and worth weighing honestly against the convenience of skipping injections altogether. A practical guide to taking semaglutide oral tablets covers the morning routine and what happens if a dose is missed, questions best answered with reference to the patient information leaflet and your prescriber.

Storage is straightforward: room temperature, no fridge. That alone makes it meaningfully more travel-friendly than the injectable pens, which require cold-chain management on longer trips.

Who the licence covers and what the NHS position is

The Wegovy tablet is licensed for adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or prediabetes. Lower BMI thresholds apply for people from certain ethnic backgrounds under UK clinical guidance, your prescriber works through this during assessment. BMI alone does not determine suitability; the full clinical picture does.

There is currently no NHS access route for the tablet. NICE would need to conduct a separate appraisal before it could be commissioned, and that process takes time. For now, the Wegovy tablet is available only via private prescription. If you are weighing up the costs and practicalities of private treatment, a breakdown of what affects the price of semaglutide tablets in the UK may be useful reading before your consultation.

People already stable on the 2.4 mg weekly injection may, subject to clinical assessment, transition directly to the 25 mg tablet rather than re-titrating from the beginning. That transition is a clinical decision, not a patient-led one. Pregnancy, breastfeeding, and trying to conceive are all contraindications; oral semaglutide is not licensed for anyone under 18. The NHS medicines page for semaglutide covers the side-effect profile and key warnings in plain language, and is worth reading alongside any prescriber consultation.

Is oral semaglutide right for you, and how a prescriber decides

The honest answer is that neither this page nor any website can tell you. What it can do is clarify the decision points. The injectable form has a longer evidence base; the 2.4 mg weekly injection has been studied across large populations, with STEP 1 trial data published in the New England Journal of Medicine showing around 15% average weight loss over 68 weeks. The tablet's trial ran for 64 weeks and produced 13.6% on average, a meaningful result, though from a smaller study population and with a strict morning routine attached.

For someone who finds injections uncomfortable, or whose schedule makes weekly pen administration genuinely difficult, the tablet may be the more sustainable option, and it is worth knowing that prescribers can also consider whether semaglutide oral drops, semaglutide oral liquid, or semaglutide oral pills might suit a patient's needs alongside the tablet format. For someone who wants the largest body of long-term evidence behind their treatment, the injectable remains the better-studied choice. Tirzepatide, available as a separate weight-loss treatment, offers a different mechanism and a different set of trial data again. A prescriber can only match treatment to you once they know your history, your lifestyle and your health goals.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day, a real clinician, not software routing your answers. If oral semaglutide UK availability, your eligibility, or the morning-routine practicalities are questions you want answered for your specific situation, speaking to our prescribers is the right next step.